Preview

Кардиоваскулярная терапия и профилактика

Расширенный поиск

Использование прямых пероральных антикоагулянтов при проведении электрической кардиоверсии

https://doi.org/10.15829/1728-8800-2021-2939

Полный текст:

Аннотация

В статье рассмотрены вопросы антикоагулянтной подготовки к проведению плановой электрической кардиоверсии у больных с персистирующей формой фибрилляции предсердий. Предложены обновленные схемы подготовки к электрической кардиоверсии и обсуждается возможность использования прямых пероральных антикоагулянтов с этой целью.

Об авторах

А. Н. Воловченко
ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)
Россия

Алексей Николаевич Воловченко — кандидат медицинских наук, зав. кардиологическим отделением клиники кардиологии УКБ № 1.

Москва. Тел.: +7 (926) 027-97-39



Д. А. Андреев
ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)
Россия

Денис Анатольевич Андреев — доктор медицинских наук, профессор, зав. кафедрой кардиологии, функциональной и ультразвуковой диагностики, директор клиники кардиологии УКБ № 1.

Москва



Д. Ф. Меситская
ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)
Россия

Динара Фератовна Меситская — кандидат медицинских наук, зав. учебной частью кафедры кардиологии, функциональной и ультразвуковой диагностики.

Москва



Список литературы

1. Roy D, Talajic M, Nattel S, et al.; for the Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667-77. doi:10.1056/NEJMoa0708789.

2. Wyse DG, Waldo AL, DiMarco JP, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-33. doi:10.1056/NEJMoa021328.

3. Van Gelder I, HagensV, Bosker H, et al. Comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834-40. doi:10.1056/NEJMoa021375.

4. Kirchhof P, Camm AJ, Goette A, et al.; EAST-AFNET 4 Trial Investigators. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383(14):1305-16. doi:10.1056/NEJMoa2019422.

5. Ha AC, Breithardt G, Camm AJ, et al. Health-related quality of life in patients with atrial fibrillation treated with rhythm control versus rate control: insights from a prospective international registry (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation: RECORD-AF). Circ Cardiovasc Qual Outcomes 2014;7(6):896-904. doi:10.1161/hcq.0000000000000011.

6. Rochlani YM, Shah NN, Pothineni NV, Paydak H. Utilization and Predictors of Electrical Cardioversion in Patients Hospitalized for Atrial Fibrillation. Cardiol Res Pract. 2016;2016:8956020.doi:10.1155/2016/8956020.

7. Новикова Н. А., Воловченко А. Н. Использование прямых пероральных антикоагулянтов при подготовке к электрической кардиоверсии. Вестник аритмологии. 2017;(88):18-24.

8. Arias MA, Casares-Medrano J, Pachón M, Puchol A. Silent embolism after electrical cardioversion of atrial fibrillation: what does brain magnetic resonance imaging provide? Rev Esp Cardiol. 2012;65(5):489. doi:10.1016/j.recesp.2011.12.010.

9. Airaksinen KE, Gronberg T, Nuotio I, et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (FinnishCardioVersion) study. J Am Coll Cardiol. 2013;62:1187-92. doi:10.1016/j.jacc.2013.04.089.

10. Hansen ML, Jepsen RM, Olesen JB, et al. Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. Europace. 2015;17(1):18-23. doi:10.1093/europace/euu189.

11. Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344(19):1411-20. doi:10.1056/NEJM200105103441901.

12. Kirchhof P, Benussi S, Kotecha D, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. doi:10.1093/eurheartj/ehw210.

13. Hindricks G, Potpara T, Dagres N, et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612.

14. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123(2):131-6. doi:10.1161/CIRCULATIONAHA.110.977546.

15. Piccini JP, Stevens SR, Lokhnygina Y, et al. Outcomes following cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013;61(19):1998-2006. doi:10.1016/j.jacc.2013.02.025.

16. Flaker G, Lopes RD, Al Khatib SM, et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014;63(11):1082-7. doi:10.1016/j.jacc.2013.09.062.

17. Cappato R, Ezekowitz MD, Klein AL, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35(47):3346-55. doi:10.1093/eurheartj/ehu367.

18. Ezekowitz MD, Pollack CV Jr, Halperin JL, et al. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J. 2018;39(32):2959-71. doi:10.1093/eurheartj/ehy148.

19. Инструкция по медицинскому применению препарата Эликвис®. Рег. уд. No: ЛП-002007-220817. http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=3f0f386b-3c8b-4c57-a3c1-10e223ae76a7&t=.

20. Telles-Garcia N, Dahal K, Kocherla C, et al. Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis. Int J Cardiol. 2018; 268:143-8. doi:10.1016/j.ijcard.2018.04.034.

21. Gibson CM, Basto AN, Howard ML. Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence. Ann Pharmacother. 2018;52(3):277-84. doi:10.1177/1060028017737095.

22. Itäinen S, Lehto M, Vasankari T, et al. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion. Europace. 2018;20:565-8. doi:10.1093/europace/eux116.

23. Russo V, Rago A, Proietti R, et al. Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. Ther Adv Drug Saf. 2017;8(2):67-75. doi:10.1177/2042098616673990.

24. Rago A, Papa AA, Cassese A, et al. Clinical Performance of Apixaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Direct Electrical Current Cardioversion: A Prospective Propensity Score-Matched Cohort Study. Am J Cardiovasc Drugs. 2019;19:421-7. doi:10.1007/s40256-019-00341-9.

25. Russo V, Rago A, Papa AA, et al. Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study. J Thromb Thrombolysis. 2018;45:206-12. doi:10.1007/s11239-017-1599-5.

26. Russo V, Di Napoli L, Bianchi V, et al. A new integrated strategy for direct current cardioversion in non-valvular atrial fibrillation patients using short-term rivaroxaban administration: The MonaldiVert real life experience. Int J Cardiol. 2016;224:454-5. doi:10.1016/j.ijcard.2016.09.022.

27. Coleman CM, Khalaf S, Mould S, et al. Novel Oral Anticoagulants for 641 DC Cardioversion Procedures: Utilization and Clinical Outcomes Compared with Warfarin. Pacing Clin Electrophysiol. 2015;38:731-7. doi:10.1111/pace.12618.

28. Frederiksen AS, Albertsen, AE, Christesen AMS, et al. Cardioversion of atrial fibrillation in a real-world setting: non-vitamin K antagonist oral anticoagulants ensure a fast and safe strategy compared to warfarin. Europace. 2018;20:1078-85. doi:10.1093/europace/eux188.

29. Klein AL, Murray RD, Grimm RA. Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. J Am Coll Cardiol. 2001;37:691-704. doi:10.1016/s0735-1097(00)01178-5.

30. Stabile G, Russo V, Rapacciuolo A, et al. Transesophageal echocardiograpy in patients with persistent atrial fibrillation undergoing electrical cardioversion on new oral anticoagulants: A multi center registry. Int J Cardiol. 2015;184:283-4. doi:10.1016/j.ijcard.2015.02.075.

31. Hohnloser SH, Cappato R, Ezekowitz MD, et al. Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial. Europace. 2016;18(2):184-90. doi:10.1093/europace/euv294.

32. Russo V, Rago A, Papa, AA, et al. Budget impact analysis of rivaroxaban vs. warfarin anticoagulation strategy for direct current cardioversion in non-valvular atrial fibrillation patients: the MonaldiVert Economic Study. Minerva Cardioangiol. 2018;66:1-5. doi:10.23736/S0026-4725.17.04500-5.

33. Papp J, Zima E, Bover R, et al. Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry. Eur Heart J Cardiovasc Pharmacother. 2017;3:147-50. doi:10.1093/ehjcvp/pvx003.

34. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of NonVitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. EP Europace. 2021:euab065. doi:10.1093/europace/euab065.


Для цитирования:


Воловченко А.Н., Андреев Д.А., Меситская Д.Ф. Использование прямых пероральных антикоагулянтов при проведении электрической кардиоверсии. Кардиоваскулярная терапия и профилактика. 2021;20(4):2939. https://doi.org/10.15829/1728-8800-2021-2939

For citation:


Volovchenko A.N., Andreev D.A., Mesitskaya D.F. Direct oral anticoagulants for electrical cardioversion. Cardiovascular Therapy and Prevention. 2021;20(4):2939. (In Russ.) https://doi.org/10.15829/1728-8800-2021-2939

Просмотров: 75


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)